TY - JOUR
T1 - Concordance of severity ratings provided in four drug interaction compendia
AU - Abarca, Jacob
AU - Malone, Daniel C.
AU - Armstrong, Edward P.
AU - Grizzle, Amy J.
AU - Hansten, Philip D.
AU - Van Bergen, Robin C.
AU - Lipton, Richard B.
PY - 2004
Y1 - 2004
N2 - Objective: To evaluate the agreement among drug-drug interaction (DDI) compendia as to designation of interactions as having the greatest clinical importance ("major" DDIs). Design: Cross-sectional, one-time evaluation. Setting: United States in fall 2001. Participants: Not applicable. Interventions: Major DDIs involving prescription medications likely to be dispensed in the community and ambulatory pharmacy settings were identified as listed in four compendia that provide specific, detailed information about DDIs (Drug Interaction Facts, Drug Interactions: Analysis and Management, Evaluations of Drug Interactions, and the MicroMedex DRUG-REAX program). Main Outcome Measure: Level of agreement between DDI compendia as assessed by the intraclass correlation coefficient (ICC). Results: Overall, 406 major DDIs were listed in one or more of the four compendia. Only 9 (2.2%) of these major DDIs were listed in all four compendia; in fact, the majority of interactions were listed in only one compendium (291 DDIs, 71.7%), despite these interactions being considered of greatest clinical relevance by at least one compendium. The ICC among the compendia was -0.092, indicating low agreement on the classification of major DDIs. Conclusion: Little agreement exists among commonly used drug interaction compendia for DDIs that were classified in fall 2001 as having the highest clinical relevance and importance. A concerted effort to identify DDIs of the highest clinical importance is needed to design effective strategies to avoid and manage them.
AB - Objective: To evaluate the agreement among drug-drug interaction (DDI) compendia as to designation of interactions as having the greatest clinical importance ("major" DDIs). Design: Cross-sectional, one-time evaluation. Setting: United States in fall 2001. Participants: Not applicable. Interventions: Major DDIs involving prescription medications likely to be dispensed in the community and ambulatory pharmacy settings were identified as listed in four compendia that provide specific, detailed information about DDIs (Drug Interaction Facts, Drug Interactions: Analysis and Management, Evaluations of Drug Interactions, and the MicroMedex DRUG-REAX program). Main Outcome Measure: Level of agreement between DDI compendia as assessed by the intraclass correlation coefficient (ICC). Results: Overall, 406 major DDIs were listed in one or more of the four compendia. Only 9 (2.2%) of these major DDIs were listed in all four compendia; in fact, the majority of interactions were listed in only one compendium (291 DDIs, 71.7%), despite these interactions being considered of greatest clinical relevance by at least one compendium. The ICC among the compendia was -0.092, indicating low agreement on the classification of major DDIs. Conclusion: Little agreement exists among commonly used drug interaction compendia for DDIs that were classified in fall 2001 as having the highest clinical relevance and importance. A concerted effort to identify DDIs of the highest clinical importance is needed to design effective strategies to avoid and manage them.
KW - Drug utilization review
KW - Drug-drug interactions
KW - Medication errors
KW - Patient safety
UR - http://www.scopus.com/inward/record.url?scp=3042701845&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=3042701845&partnerID=8YFLogxK
U2 - 10.1331/154434504773062582
DO - 10.1331/154434504773062582
M3 - Article
C2 - 15098847
AN - SCOPUS:3042701845
SN - 1544-3191
VL - 44
SP - 136
EP - 141
JO - Journal of the American Pharmaceutical Association. American Pharmaceutical Association
JF - Journal of the American Pharmaceutical Association. American Pharmaceutical Association
IS - 2
ER -